Clinical Cardiology Alert – November 1, 2005
November 1, 2005
View Issues
-
Pharmacology Watch
Roche is Under Pressure Over Its Antiviral Drug Tamiflu; ACE Inhibitors or ARBs for Prediabetics?; Xigris is Approved for Severe Sepsis; ACE Inhibitors Inhibiting Aortic Valve Stenosis?; FDA Actions -
Clinical Briefs in Primary Care supplement
-
Volume Outcome Relationships in the Stent Era
Volume outcome data for percutaneous coronary interventions (PCI) was largely collected and reported in the balloon angioplasty era. Thus, this report from New York state's PCI reporting system from 1998 to 2000 is of interest. This database of over 100,000 cases, which can be adjusted for severity of illness, was interrogated for 3 outcomes: in-hospital mortality, same-day coronary artery bypass surgery (CABG), and same-stay CABG. -
Early Invasive vs Selectively Invasive Management for Acute Coronary Syndrome
An early invasive strategy did not result in an expected differential in the primary end point. -
Vasodilators for Aortic Regurgitation
Long-term vasodilator therapy with either nifedipine or enalapril changed neither the hemodynamic burden of severe aortic regurgitation nor reduce or delay the need for valve replacement surgery in asymptomatic patients with chronic severe aortic regurgitation and normal LV function. -
Unmasking of Brugada Syndrome By Lithium
Lithium can unmask latent Brugada syndrome by blockade of susceptible cardiac sodium channels. -
Gender Differences in Systemic Embolism Risk in Atrial Fibrillation
Women have a higher risk than men for atrial fibrillation related thromboembolism that is independent of the presence of other risk factors. -
B2 Adrenergic Receptor Genotype and Survival After an Acute Coronary Syndrome
The 79 CC and 46 AA alleles studied were found to be high long term survival, further validating pharmacogenetic targeting of b blocker therapy for improving ACS results.